Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||
1 November 1996 | Volume 125 Issue 9 | Page 780
I question the propriety of bone marrow transplantation in patients with chronic lymphocytic leukemia (CLL) in Rai stages 0, 1, or 2 who may be asymptomatic for years without any specific treatment. As reported by Michallet and colleagues [1], 23 of the 54 transplant recipients had disease in Rai stage 0, 1, and 2 at the time of transplantation. Nonetheless, 25 (46%) died of treatment-related complications. How can one justify such a riskbenefit ratio? Although Rai stage 3 or 4 disease is associated with a relatively short median survival, this is not the case for early-stage CLL, in which the prognosis is often good for many years. Michallet and colleagues' Table 1 indicates that 10 of the 23 patients with Rai stage 0, 1, and 2 disease died of complications related to bone marrow transplantation, an unacceptably high mortality rate for a disease that is otherwise indolent until it reaches stage 3 or 4.
What type of informed consent was obtained from these patients? Were they apprised of the possible lethality of bone marrow transplantation? Did the ethics committees at the various institutions approve of this procedure for patients with early-stage CCL? I am deeply troubled by the report of Michallet and colleagues and somewhat surprised that these concerns were not raised by the reviewers of the manuscript or by the editors of Annals.
1. Michallet M, Archimbaud E, Bandini G, Rowlings PA, Deeg HJ, Gahrton G, et al. HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. Ann Intern Med. 1996; 124:311-5. About Letters
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
LETTER
Allogeneic Bone Marrow Transplantation in Chronic Lymphocytic Leukemia
TO THE EDITOR:
Author and Article Information
![]()
Top
Author & Article Info
REFERENCE
Mt. Sinai School of Medicine New York, NY 10029.
REFERENCE
![]()
Top
Author & Article Info
REFERENCE
![]()
Include no more than 300 words of text, three authors, and five references
Type with double-spacing
Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
This article has been cited by other articles:
![]() |
J. G. Gribben The Role of Stem Cell Transplantation in Chronic Lymphocytic Leukemia ASCO Educational Book, January 1, 2008; 2008(1): 291 - 296. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. J. Hlubocky, M. J. Ratain, M. Wen, and C. K. Daugherty Complementary and Alternative Medicine Among Advanced Cancer Patients Enrolled on Phase I Trials: A Study of Prognosis, Quality of Life, and Preferences for Decision Making J. Clin. Oncol., February 10, 2007; 25(5): 548 - 554. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Muller, G. Tsakou, F. Grunebach, S. M. Schmidt, and P. Brossart Induction of chronic lymphocytic leukemia (CLL)-specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells Blood, March 1, 2004; 103(5): 1763 - 1769. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Markman Safety Issues in Using Complementary and Alternative Medicine J. Clin. Oncol., September 15, 2002; 20(90001): 39s - 41. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. C. Gotay and D. Dumitriu Health Food Store Recommendations for Breast Cancer Patients Arch Fam Med, August 1, 2000; 9(8): 692 - 698. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||